Cargando…
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy. The main chemotherapy protocol for this type of tumor is based on temozolomide (TMZ), albeit with limited success. Cisplatin is widely used to treat several types of tumor and, in association with TMZ...
Autores principales: | Rocha, C R R, Garcia, C C M, Vieira, D B, Quinet, A, de Andrade-Lima, L C, Munford, V, Belizário, J E, Menck, C F M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649538/ https://www.ncbi.nlm.nih.gov/pubmed/25356874 http://dx.doi.org/10.1038/cddis.2014.465 |
Ejemplares similares
-
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
por: Rocha, C R R, et al.
Publicado: (2015) -
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
por: Rocha, Clarissa Ribeiro Reily, et al.
Publicado: (2016) -
DNA repair pathways and cisplatin resistance: an intimate relationship
por: Rocha, Clarissa Ribeiro Reily, et al.
Publicado: (2018) -
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide
por: Weyhenmeyer, Birgit C., et al.
Publicado: (2016) -
Targeting autophagy to sensitive glioma to temozolomide treatment
por: Yan, Yuanliang, et al.
Publicado: (2016)